PSNL News and Press, Personalis Inc. From 12/14/22

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that John West, co-founder, CEO and member of the board of directors of Personalis, notified the Company of his decision to retire as CEO and a director at the end of the calendar year. Mr. West...

Personalis, Inc. (Nasdaq: PSNL) today announced a collaboration with UC San Francisco (UCSF) that will deploy a personalized liquid biopsy-based research use only (RUO) assay for a study of patients with colorectal cancer. The research efforts will use Personalis’ NeXT Personal ™...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that its management team will present at the 34 th Annual Piper Sandler Healthcare Conference on Wednesday, November 30, 2022 at 1:30 p.m. Eastern Time in New York, NY. About Per...

Personalis, Inc. (Nasdaq: PSNL) today announced that the company will share data resulting from expanded features of its NeXT Platform® at the Society for Immunotherapy of Cancer (SITC) Annual Meeting , November 8-12 in Boston, with three abstracts that highlight advanced R&...

Personalis, Inc. (PSNL) Q3 2022 Earnings Conference Call November 2, 2022 17:00 ET Company Participants Caroline Corner - Investor Relations John West - President and Chief Executive Officer Aaron Tachibana - Chief Financial Officer Conference Call Particip...

Personalis press release ( NASDAQ: PSNL ): Q3 GAAP EPS of -$0.58 beats by $0.06 . Revenue of $14.9M (-33.2% Y/Y) beats by $1.26M . Gross margin was 16.7% in the three months ended September 30, 2022 Operating expenses were $29.7 million in the three months ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the third quarter ended September 30, 2022. Third Quarter and Recent Highlights Reported quarterly revenue of $14.9 million in the third quarter of 2...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the appointment of Christopher Hall as SVP and Head, Diagnostics Business. As part of the executive leadership team, Hall will drive the vision and strategy for commercializing Personalis’ ...

Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that it will release its third quarter 2022 financial results on Wednesday, November 2, 2022. In conjunction with the release, Personalis will host a conference call and webcast that d...

Summary ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. UiPath, Ginkgo Bioworks, and NVIDIA were increased while decreasing Spotify, Ionis Pharma, CRISPR Therapeutics, and Coinbase Global. The top three positions are Tesla Inc., Zoom Vid...